NCT04008030 2025-10-03CheckMate 8HWBristol-Myers SquibbPhase 3 Active not recruiting839 enrolled 22 charts 1 FDA
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts